What makes MS documentation particularly demanding?
MS is a complex, heterogeneous disease with a course that varies from benign to rapidly disabling. Documentation must capture not just the current visit but the patient's entire disease history: MS type (relapsing-remitting, secondary progressive, primary progressive), date of diagnosis, initial presentation, relapse history with dates and recovery, MRI findings over time, and all prior disease-modifying therapies with efficacy and tolerability.
For patients on high-efficacy therapies — natalizumab, alemtuzumab, cladribine, ocrelizumab — safety monitoring documentation is required: JC antibody titers, complete blood counts, immunoglobulin levels, and the clinical rationale for continuing high-efficacy therapy despite risk.
This documentation complexity exceeds the capability of any general-purpose AI scribe. A system without MS-specific training will miss the structured elements that MS neurologists depend on.
How should EDSS and disease progression be documented?
The Expanded Disability Status Scale (EDSS) is the standard measure of neurological disability in MS. It should be calculated and recorded at each visit — not just when the neurologist believes the patient has changed, but consistently across all visits to permit accurate tracking of disability progression.
Documentation of EDSS requires recording the findings of a structured neurological examination across the seven functional systems (pyramidal, cerebellar, brainstem, sensory, bowel/bladder, visual, cerebral) and the patient's ambulation status. Each component must be documented to support the EDSS calculation.
For progressive MS, documenting consistent EDSS increase over 6 or 12 months is the clinical evidence that supports both treatment escalation decisions and prior authorization for high-efficacy therapies in patients who have failed or are at risk of failing lower-efficacy options.
How does documentation support disease-modifying therapy authorizations?
Disease-modifying therapy prior authorization for MS requires documentation of the diagnosis with supporting criteria, disease course and activity level, prior therapy history with reasons for discontinuation, current disability level, and clinical rationale for the specific therapy being requested.
For patients stepping up from platform therapies to high-efficacy agents, the documentation must show evidence of breakthrough disease — new relapses, new MRI lesions, or EDSS progression — despite adequate treatment with the current therapy. This evidence must be in the longitudinal clinical record, not reconstructed at the time of the authorization request.
Scryber's structured MS documentation workflow captures all of these elements at each visit, so the prior authorization package at the time of a therapy change is a summary of existing documentation rather than an emergency documentation effort.
See It in Practice
See how Scryber works for your practice
Transcryber captures every encounter. Visualyzer shows you what you earned, what you collected, and where the gap is.